Welcome to our dedicated page for ZIMMER BIOMET HOLDINGS SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZIMMER BIOMET HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZIMMER BIOMET HOLDINGS's regulatory disclosures and financial reporting.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity involving restricted stock units (RSUs) tied to the company’s common stock. On 11/28/2025, RSUs covering 56.534 shares and 122.695 shares were settled into common stock at an exercise price of $0 per share, reflecting previously granted awards becoming deliverable. On the same date, 56.534 shares and 122.695 shares of common stock were withheld at a price of $97.52 per share to cover FICA and related tax obligations associated with her retirement eligibility under the terms of those awards. Following these transactions, she directly holds 6,833 shares of common stock, along with remaining RSUs that vest on March 6, 2026, and in two tranches on February 20, 2026 and February 20, 2027.
Zimmer Biomet Holdings (ZBH) reported an insider equity transaction by its Exec VP & CFO, Suketu Upadhyay. On November 10, 2025, 10,632 performance-based RSUs vested and were converted into common stock at $0 per share. To cover taxes, 4,731 shares were withheld at a price of $87.73 per share.
Following these transactions, the executive’s directly held common stock totaled 54,754 shares. The filing notes these RSUs each represented the right to receive one share of common stock, and the earned performance-based RSUs vested on November 10, 2025.
Zimmer Biomet (ZBH) reported third‑quarter results. Net sales were $2,001.4 million, up from $1,824.2 million. Operating profit rose to $351.3 million from $279.5 million, while net earnings attributable to the company were $230.9 million versus $249.1 million a year ago. Diluted EPS was $1.16 (prior year $1.23). By category, Q3 sales were Knees $792.4 million, Hips $506.2 million, S.E.T. $541.5 million, and Technology & Data, Bone Cement and Surgical $161.3 million.
For the first nine months, net sales reached $5,987.7 million with operating cash flow of $1,179.7 million. The balance sheet showed cash and cash equivalents of $1,292.7 million and long‑term debt of $7,512.6 million as of September 30, 2025. The company completed the Paragon 28 acquisition, paying $1,241.5 million in cash plus contingent consideration fair‑valued at $35.0 million, recording $635.6 million of goodwill. During 2025, Zimmer Biomet issued new senior notes (including $1,748.1 million in U.S. dollar notes and $744.0 million in Swiss Notes) and redeemed $863.0 million of 2025 notes. A quarterly dividend of $0.24 per share was declared.
Zimmer Biomet Holdings, Inc. furnished an 8-K announcing a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and its information is incorporated by reference in the report.
The Item 2.02 information, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference. An additional Exhibit 104 (Cover Page Interactive Data File) is included.
Zimmer Biomet Holdings (ZBH) reported an insider equity award on a Form 4. The company’s Executive Vice President and CFO received 10,632 restricted stock units (RSUs), recorded as an acquisition at $0 per unit and held directly.
The RSUs were part of a performance-based grant made on September 1, 2023, with results measured over October 1, 2024 to September 30, 2025. On October 24, 2025, the final outcome was determined, and 10,632 RSUs were earned. Each RSU represents the right to receive one share of Zimmer Biomet common stock. The earned RSUs are scheduled to vest on November 10, 2025.
Zimmer Biomet Holdings, Inc. completed its acquisition of Monogram Technologies Inc. through a merger on October 7, 2025, making Monogram a wholly owned subsidiary. At the merger’s effective time, each share of Monogram common stock was converted into the right to receive $4.04 in cash, without interest, plus one contractual contingent value right under a Contingent Value Rights Agreement with Computershare Trust Company, N.A. Each share of Monogram Series D preferred stock became entitled to $2.25 in cash, without interest, plus any accrued but unpaid dividends, and each share of Series E preferred stock became entitled to $100.00 in cash, without interest. The company also issued a press release on October 7, 2025 announcing the merger closing.
Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 140.163 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The derivative units convert on a 1-for-1 basis into common stock and are scheduled to be settled in shares within sixty days after the director’s service ends. The report shows 1,613.887 shares of common stock beneficially owned following the reported transaction, and it notes 3.428 phantom units were added on 07/31/2025 via the plan’s dividend reinvestment provision.
Kolli Sreelakshmi, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 159.276 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The units convert 1-for-1 into common shares and are to be settled in company stock within sixty days after the director stops service. Following the transaction, the report shows beneficial ownership of 5,393.594 shares (including 13.119 units added via dividend reinvestment on 07/31/2025). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported an acquisition of 344.036 phantom stock units on 09/30/2025 under the companys Deferred Compensation Plan for Non-Employee Directors. The phantom units convert 1-for-1 into common stock value and are to be settled in cash in ten annual installments commencing within 60 days after the end of the calendar year in which her director service ends. The report notes 26.33 of the units were credited on 07/31/2025 via the plans dividend reinvestment provision. Following the transaction the filing shows total beneficial ownership of 10,875.718 shares.
Robert Hagemann, a non-employee director of Zimmer Biomet Holdings, Inc. (ZBH), was granted 280.326 phantom stock units on 09/30/2025 under the company's Deferred Compensation Plan for Non-Employee Directors. The units convert on a 1-for-1 basis into common stock value and are recorded at a per-unit price of $98.1, producing a reported aggregate value of $31,207.57. The filing notes that 79.18 of the units were accrued on 07/31/2025 under a dividend reinvestment provision. The phantom units are payable in cash in five annual installments beginning within 60 days after the calendar year in which the director's service ends.